Boothbay Fund Management’s BioXcel Therapeutics BTAI Stock Holding History

Boothbay Fund Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,688	Closed	-$504K	–	1848
2023 Q1	$504K	Sell	1,688 -1,465	-46%	-$626K	0.01%	1252
2022 Q4	$1.08M	Buy	+3,153	New	+$762K	0.03%	857
2021 Q3	–	Sell	-449	Closed	-$209K	–	1907
2021 Q2	$209K	Buy	+449	New	+$245K	0.01%	1497
2020 Q3	–	Sell	-2,054	Closed	-$1.54M	–	1054
2020 Q2	$1.74M	Sell	2,054 -3,268	-61%	-$2.13M	0.12%	233
2020 Q1	$1.9M	Buy	5,322 +3,681	+224%	+$1.32M	0.16%	162
2019 Q4	$384K	Buy	+1,641	New	+$165K	0.03%	553

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Boothbay Fund Management's BTAI Position: Q2 2023 in Review

Boothbay Fund Management sold out of BioXcel Therapeutics (BTAI) in Q2 2023, closing a stake of 1,688 shares — an estimated $504K sold.

Boothbay Fund Management first reported a position in BTAI in Q4 2019 and held it in 6 quarters. The position peaked at $1.9M in Q1 2020. 88 funds tracked by Wall St. Rank hold BTAI as of Q2 2023.

Boothbay Fund Management reported no remaining BioXcel Therapeutics position as of Q2 2023 after selling out during the quarter.
Boothbay Fund Management sold 1,688 BioXcel Therapeutics shares in Q2 2023, an estimated $504K.
Boothbay Fund Management first reported a position in BioXcel Therapeutics in Q4 2019 and held it in 6 quarters.
Boothbay Fund Management's BioXcel Therapeutics position peaked at $1.9M in Q1 2020.
88 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2023.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.